Sciatica Treatment Market Size, Share, Growth Analysis, By Drug class(Non-steroidal anti-inflammatory drugs, Steroids, Antidepressants and Others), By Type(Acute sciatica, Chronic sciatica, and Others), By Distribution channel(Hospital pharmacies, Retail & specialty pharmacies, and Online providers), By Region - Industry Forecast 2024-2031

Sciatica is a prevalent condition with a lifetime occurrence rate reaching up to 43%, affecting approximately 10-40% of the population, with higher rates observed in older age groups. The increasing incidence of both chronic and acute sciatica among individuals serves as a significant driver propelling the growth of the Sciatica Treatment Market. According to the MMR Study, sciatica exerts its impact on a substantial percentage of the population, ranging from 10-40%, with a more pronounced prevalence in older age brackets. Notably, adults aged 20-59 display a prevalence of 13.1%, while individuals aged 60 and above experience a higher rate of 19.2%, underscoring the heightened impact within older demographics. 

Surgical procedures like microdiscectomy or spinal fusion, often recommended for sciatica, come with substantial costs. Additionally, emerging treatments such as stem cell therapy, while promising, entail higher expenses, and there's a possibility that insurance coverage may not extend to these procedures. The elevated costs associated with these treatments pose a significant barrier, limiting access to certain therapeutic options, particularly for patients in low- and middle-income countries where healthcare resources are already constrained.